SKYRIZI Targets a Key Source of Inflammation

SKYRIZI is the first FDA-approved treatment for both ulcerative colitis (UC) and Crohn’s disease that specifically targets the interleukin-23 (IL-23) protein, one of the key proteins responsible for inflammation. By targeting IL-23, SKYRIZI can help reduce the excess inflammation that can contribute to UC symptoms.

Watch this video to learn how SKYRIZI works.

SKYRIZI is approved for adults with moderate to severe ulcerative colitis or moderate to severe Crohn’s disease.

Is SKYRIZI Right for You?

If you’re still experiencing symptoms on your current treatment, partner with your gastroenterologist to see if SKYRIZI is the right treatment option for you. Check out some questions to ask your doctor at your next appointment.

See questions to ask your gastroenterologist

Up Next

Learn how to make SKYRIZI part of your routine.

Recommended for You

Discover how SKYRIZI can help deliver significant symptom relief—and more. 

Answer 5 quick questions to better understand how UC is impacting you.